Patients with autoimmune lymphoproliferative syndrome (ALPS) and lymphoproliferation (LPR) 
Introduction
Fas-deficient lymphoproliferation (LPR) and FasL-deficient generalized lymphoproliferative disease (GLD) mice, and humans with autoimmune lymphoproliferative syndrome (ALPS) develop marked lymphoproliferation. They also exhibit lupus-like autoimmunity that is largely dependent on B cells [1] and CD4 + T cells [2, 3] . Furthermore, they accumulate large numbers of TCRab + CD4 2 CD8 2 double negative (DN) T cells. The function of DN T cells in LPR mice is not clear. Two published studies have illustrated that these cells can exert regulatory function outside the LPR context, toward T cells responding to alloantigens [4, 5] . Within Fas-deficient mice and humans, however, evidence suggests that DN T cells contribute to disease, either by promoting further lymphocyte accumulation [6] or by promoting autoimmune tissue injury [7, 8] . It has long been recognized, however, that the DN T cell compartment of LPR mice is heterogeneous and may contain cells with differing functional properties [9] . Hence, the identification of molecules that segregate with specific DN T cell functions is of interest.
The common c subunit of the activating Fc receptors, FcRc, is a signal transducing adaptor protein that plays a central role in linking the specificity of immunoglobulins with the effector functions of the innate immune system [10] . It is critical to NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis by macrophages, and mast cell responses to IgE crosslinking [11] . FcRc is also highly homologous to the key T cell receptor (TCR) signaling molecule, CD3f [12] and can substitute for it during T cell development [13] . FcRc has been found in the TCR complexes of certain intraepithelial T cells [14, 15] , the CD4 + and CD8 + T cells of lupus patients [16] , and human effector CD4 + T cells [17] . FcRc-containing TCR complexes have been associated with some differences in signal transduction compared with CD3f-containing ones [18, 19] . However, the specific immunological consequences of FcRc expression in T cells have not been clearly demonstrated.
DN T cells bearing the L d -specific 2C transgenic TCR have been shown to be capable of inhibiting allogeneic immune responses mediated by L d -specific 2C CD8 + T cells [20] , including the rejection of skin [20, 21] and cardiac [22] allografts, and GVHD [23] . We observed that among 1099 genes differentially expressed between regulatory and non-regulatory DN T cell clones, FcRc was the most highly upregulated in the regulatory ones [24] . We subsequently showed that FcRc inclusion in the TCR complex of 2C DN T cells was required for their regulatory function [25] . Whether FcRc expression is required for non-transgenic DN T cells to perform regulatory functions is not known.
To determine whether FcRc might play a role in the regulatory function of LPR DN T cells, we generated LPR FcRc 2/2 mice on the C57BL/6 background and observed that they exhibited increased T cell accumulation and early mortality compared with LPR FcRc +/+ mice [26] . This observation led us to hypothesize that FcRc expression by LPR DN T cells might participate in controlling lymphocyte accumulation in LPR mice. Here, we show that FcRc expression is critical for LPR DN T cells to exert regulatory function toward Fas-sufficient CD4
+ and CD8 + T cells responding to auto-and allo-antigens in vitro and in vivo. In addition, FcRc cell-intrinsically determined the rate of DN T cell accumulation in LPR mice. Hence, our data reveal that FcRc plays an important role in controlling the function and survival of LPR DN T cells.
Results

A Subset of FcRc + LPR DN T Cells Exhibits an Effectormemory Phenotype
FcRc is well-known to be expressed in myeloid cells, NK cells and B cells but its expression in T cells is less common. We recently observed that in contrast to CD4 + or CD8 + T cells, a significant proportion of DN T cells co-expresses FcRc and surface Fcc receptor IIIA (CD16) [26] . Since little is known about FcRc + DN T cells, we further characterized this population of cells. To examine their expression of T cell activation and memory markers, splenocytes from B6 and LPR mice were stained for expression of TCRb, CD4, CD8, NK1.1, CD16/32 and CD44, CD62L, or CD25. As shown in Fig. 1A 
2 , CD8 2 , NK1.1 2 ) exhibited higher levels of CD44 expression, and lower levels of CD62L expression, in comparison with CD16
2 DN T cells within the same mice. Although LPR DN T cells are known to have an activated phenotype with high levels of CD44 expression [9, 27] , we observed even higher levels of CD44 expression on the CD16 + subset (Fig. 1A , top right panel and Fig. 1B) . A higher level of CD25 expression was also seen in the CD16-expressing subset (data not shown). Hence in both normal B6 mice and Fas-deficient LPR mice, an FcRc-expressing subset of DN T cells displays an effector-memory phenotype. ) and assessed their expansion in the peripheral blood at days 1, 5, 7, 10, and 14. As shown in Fig. 2B , both types of DN T cells accounted for a very small fraction of PBMCs until day 14, when preferential expansion of LPR FcRc 2/2 DN T cells was evident (two-way repeated measures ANOVA p = 0.0279 for the effect of FcRc). Similarly, when splenic DN T cell counts were determined at day 7, a similar number were found in recipients of both types of DN T cell; at day 14, however, the number of DN T cells recovered from recipients of LPR FcRc 2/2 DN T cells was approximately 5 times greater (Fig. 2C , two-way ANOVA p = 0.0005 for the effect of FcRc expression by transferred DN T cells). Together, these data suggest that FcRc expression in DN T cells limits their proliferation in vitro and in a lymphopenic environment.
FcRc Restrains DN T Cell Expansion in vitro and in vivo
FcRc-expressing DN T Cells are Lost with Increasing Lymphocyte Accumulation
In order to understand the relationship between FcRc expression in DN T cells and the development of lymphoproliferative disease, we compared DN T cell FcRc/CD16 expression in younger (,12 weeks of age) and older (,16 weeks of age) LPR mice and observed a loss of this subset as lymphocytes accumulated (Fig. 3A, Fig. S1A and Fig. 3B-C) . These observations suggest that the loss of CD16 hi DN T cells with increasing lymphocyte accumulation is likely due to a higher rate of apoptosis within this population.
The Ability of LPR DN T Cells to Control Lymphoproliferative Disease Depends on Both FcRc and Fas
Since FcRc-expressing 2C TCR transgenic DN T cells possess regulatory function [25] [4, 20, 28, 29] . We hypothesized that an FcRc-dependent regulatory function of LPR DN T cells might also require Fas-FasL interaction. To determine whether the inability to inhibit lymphoproliferation might be due to the lack of functional Fas expression in LPR mice, we tested the role of FcRc in LPR DN T cell function in GLD mice. These animals develop a lymphoproliferative disease identical to that of LPR mice as a result of the absence of functional FasL. Six-week-old GLD mice were treated with either LPR FcRc +/+ or LPR FcRc To validate the requirement of Fas expression on responder cells, the same experiment was performed using purified CD8 + T cells from Fas mutant LPR mice. Consistent with the finding in 2/2 DN, n = 7 and n = 9, respectively). They were then followed daily for survival. As shown in Fig. 5C , LPR FcRc +/+ , but not LPR FcRc 2/2 , DN T cells could rescue recipients from lethal GVHD (log rank p = 0.01). Taken together, these data illustrate that expression of FcRc in LPR DN T cells is critical for their ability to regulate alloantigen-reactive Fas + T cells. Since FcRc expression in LPR DN T cells is correlated with surface expression of CD16 [26] , we attempted to sort DN T cells into CD16 hi and CD16 lo populations for use in suppression assays and in vivo experiments. These attempts were not successful, possibly due to the high rate of apoptosis in the CD16 hi compartment (Fig. 3B-C and [26] ). Therefore, we sought confirmation of our observations on the role of FcRc in a different population of DN T cells. To this end, we infused Fas-sufficient FcRc +/+ and FcRc 2/2 B6 mice with allogeneic bm1 splenocytes and, 7 days later, enriched DN T cells from their secondary lymphoid organs and used them as putative suppressor cells. Naïve FcRc +/+ B6 CD8 + T cells were stimulated by irradiated bm1 
Suppression of Fas-sufficient T cells by LPR DN T Cells Results in the Fas-mediated Cytolysis of Responding T Cells
Much of the literature on DN Tregs demonstrates that these cells inhibit T cell responses via the Fas pathway (reviewed in [30, 31] ), and this is true for LPR DN T cells as well [4, 29] . While Fas-mediated cytolysis of activated T cells is well described, there are also data to show that Fas ligation on naïve T cells can inhibit their initial activation without causing apoptosis [32, 33] . We recently demonstrated that proliferating, alloreactive Fas + CD4 + T cells were selectively killed by LPR DN T cells during a CFSE suppression assay [29] . To determine whether this is also true for CD8 + T cells, we co-cultured CFSE-labelled B6 or LPR CD8 + T cells with irradiated CB6F1 splenocytes and IL-2. LPR DN T cells were added to the cultures in varying ratios and after 5 days, CFSE dilution and 7-AAD staining were jointly examined in CD8 + T cells by flow cytometry. As shown in Fig. 6A , the proliferation of Fas-expressing, but not Fas-deficient, CD8
+ T cells was suppressed by LPR DN T cells (two-way ANOVA p,0.0001).
We then examined CD8 + T cell death amongst unproliferated (CFSE hi ) and proliferated (CFSE-diluted) cells. As shown in 
Discussion
In this study, we showed that FcRc expression in LPR DN T cells is critical for their ability to suppress CD4 + and CD8 + T cells responding to auto-and allo-antigens, and that this suppression requires FasL-Fas interactions. FcRc-deficient LPR DN T cells showed greatly reduced regulatory function toward B6 CD4 + and CD8 + T cells responding to alloantigens in vitro and attenuate CD4 + T cell induced GVHD (Fig. 5) . In our previous study [25] [13, 14, 25, 34, 35] . Our data therefore suggest that TCR-derived signals are likely to be important for the function of LPR DN T cells as Tregs.
In addition to suppressing alloreactive T cells, we found that adoptively transferred FcRc-sufficient LPR DN T cells inhibited the progressive accumulation of lymphocytes in GLD mice, whereas FcRc 2/2 LPR DN T cells failed to do so (Fig. 4B) . This finding suggests that FcRc expression in LPR DN T cells can also play a part in controlling autoimmune lymphoproliferative disease. In contrast to the effect on GLD mice, adoptive transfer of the same number of FcRc-sufficient LPR DN T cells failed to inhibit the accumulation of T cells in FcRc 2/2 LPR mice (Fig. 4B) . In fact, transfer of LPR DN T cells, regardless of their FcRc genotype, resulted in an increased total lymphocyte count in LPR.FcRc 2/2 mice (Fig. 4B, right column) . This observation is consistent with the recent finding that DN T cells can drive T cell accumulation in this Fas-deficient context [6] . Since GLD mice express functional Fas whereas LPR mice do not, our observations further indicate that FcRc-mediated signaling is required for LPR DN T cells to provide a FasL-mediated death signal toward target cells. Consistent with this notion, we found that LPR FcRc +/+ DN T cells could inhibit B6 but not LPR CD8 + T cell proliferation in response to alloantigen stimulation (Fig. 6A) . Furthermore, suppression of CD8 + T cells was mainly due to the killing of proliferated CD8 + T cells (Fig. 6B-C) . LPR DN T cells are known to express FasL constitutively [36, 37] . However, those studies did not examine differences in FasL surface expression in response to TCR stimulation, which has been shown to mediate FasL translocation from intracellular compartments to the cell surface [38, 39] . We have recently demonstrated that this is also true for LPR DN T cells, in that the combination of TCR stimulation and autocrine IFNc secretion and signaling was required for efficient externalization of presynthesized FasL on the cell surface, leading to regulatory function in vitro and in vivo [29] . The present study extends these findings by illustrating that the FasL-mediated regulatory function of LPR DN T cells also requires FcRc. We have not tested how FcRc might participate in this process, but it is possible that a signal arising from FcRc, but not CD3f, might be required to trigger sufficient IFNc release to cause FasL externalization; alternatively, FcRc-derived signals might be required independently of IFNc secretion and signaling. These hypotheses will require further experimental testing.
In addition to Fas expression, another major difference between GLD and LPR FcRc (Fig.  S2A-B) . Similarly, although CD4
+
Foxp3
+ Tregs are known to control lymphoproliferation and autoimmunity [40] , examination of LPR lymph node CD4 + T cells revealed that FcRc-expressing cells were distinct from the Foxp3 + population (Fig. S2C) . Thus, it appears that the inability of FcRc +/+ LPR DN T cells to inhibit the progression of lymphocyte accumulation in FcRc 2/2 LPR mice is due to the lack of functional Fas rather than a functional impairment of other FcRc-expressing cells in recipient mice.
In addition to requiring expression of FcRc in order to suppress the proliferation of Fas + CD4 + and CD8 + T cells (a cell-extrinsic function of FcRc), LPR DN T cells also showed cell-intrinsic (triangles) mice were added to the MLR cultures as putative suppressor cells. Cell proliferation was measured by 3 H-thymidine incorporation. The data are expressed as percent inhibition of proliferation as compared with the controls to which no putative suppressor cells were added. Data points are the mean +/2 SD of triplicate wells and are derived from one of three independent experiments. doi:10.1371/journal.pone.0065253.g005 differences in the propensity to accumulate in vitro and in vivo on the basis of their FcRc genotype. Proliferation of FcRc + DN T cells was significantly reduced compared with FcRc 2 DN T cells in vitro, and the former accumulated to a much lesser extent after adoptive transfer into B6 SCID mice (Fig. 2) . This finding is consistent with our recent observation that FcRc-expressing DN T cells show a high rate of apoptosis in vivo compared with FcRc deficient DN T cells (Fig. 3 and [26] ). To our knowledge, FcRc signaling in T cells has not previously been associated with apoptosis, although it has been described to mediate the death of NK cells and granulocytes in certain circumstances [41] [42] [43] . Further, while TCRs that contain FcRc have been shown to result in hyperresponsiveness to TCR signaling [19] , only limited data exist on specific differences in T cell function resulting from FcRc incorporation in the TCR complex [18, 25] .
Given the differing roles played by FcRc in this study, it is interesting to note that a population of short-lived Foxp3 + Tregs induced by donor-specific splenocyte infusion and capable of inhibiting allograft rejection has recently been identified [44] . These Tregs expressed T cell immunoglobulin and mucin domain-3 (TIM-3), which is commonly expressed on activated Th1 and Th17 cells [45] [46] [47] . Interestingly, although TIM-3 + Tregs could more potently inhibit effector T cells than TIM-3 2 Tregs in vitro and preferentially infiltrated skin allografts, they expressed PD-1 and were susceptible to galectin-9-mediated death and actually exhibited reduced potency upon adoptive transfer [44] . These data suggest that potent Tregs are carefully controlled by mechanisms that promote both their regulatory function and their clearance in vivo. Our data suggest that FcRc might play a similar role in DN T cells, although further work will be required to investigate this function of FcRc. DN T cells in LPR mice are a heterogeneous population. A recent study has suggested that LPR DN T cells can stimulate, rather than inhibit the expansion of CD4 + and CD8 + T cells within LPR mice by promoting the expansion of the follicular dendritic cell network [6] . Currently, no marker that can distinguish regulatory and non-regulatory DN T cells has yet been identified. Together with our previous study [25] , the data presented here suggest that FcRc expression by DN T cells is required for these cells to exert regulatory function. Our previous work also showed that FcRc was the most differentially expressed gene between regulatory DN T cell clones and their nonregulatory mutants [24] . Collectively, these findings suggest that FcRc might serve as a novel marker for DN Tregs. It will be of interest to determine whether human DN T cells [48, 49] express FcRc, and whether it confers regulatory function upon them as well. If so, it will be important to examine whether FcRcexpressing DN T cells are a unique lineage developing under different stimuli, or whether they can differentiate from FcRc 2 DN T cells. These studies could lead to the identification of DN Treg-specific lineage specification factors, and therefore represent a critical direction for future research.
In conclusion, FcRc exhibited two distinct functions in LPR DN T cells: cell-extrinsic regulation of Fas + T cell proliferative responses to allo-and auto-antigen, and cell-intrinsic regulation of DN T cell accumulation within the LPR setting. Additional studies will be required to better define the role of FcRc in DN T cell regulatory function and whether FcRc is a universal marker of regulatory DN T cells. 
Materials and Methods
Ethics Statement
Antibodies and Flow Cytometry
The following mAbs were obtained from BioLegend (San Diego CA): FITC-conjugated anti-CD3, anti-CD4, anti-CD8, antiTCRb, and anti-NK1.1; PE-conjugated anti-CD3, anti-CD4, anti-CD8, and anti-NK1.1; PerCP-Cy5.5-conjugated anti-NK1.1; PE-Cy7-conjugated anti-CD4; allophycocyanin-conjugated antiFoxp3, anti-CD4 and anti-CD8; allophycocyanin-Cy7-conjugated anti-CD4 and anti-CD8; PE-Cy5-conjugated anti-CD8; Alexa Fluor 700-conjugated anti-TCRb; and purified anti-CD28. Purified rabbit anti-mouse FcRc mAb was obtained from Upstate Cell Signaling Solutions (Lake Placid NY). PE-conjugated donkey anti-rabbit F(ab9) 2 was obtained from eBioscience. Purified anti-CD3 mAb was prepared from the 145-2C11 hybridoma (ATCC, Manassas VA) in house. PE-conjugated annexin V was from BioLegend.
Fixation and intracellular staining was performed using either the eBioscience intracellular staining kit. Flow cytometry was performed on an LSR II (BD Biosciences), an Accuri C6 (BD Biosciences), or an EPICS-XL (Beckman-Coulter). + cells with PE-conjugated antibodies and anti-PE microbeads. Anti-CD3 microbeads were then used to separate the negative fraction into DN T cells and CD3
Cell Purification
2 CD19 2 components. The CD3 + fraction contained .90% DN T cells (the remainder included some NK T cells). The CD3 2 fraction was .90% free of CD3 + cells. Additional columns were used as required to achieve these levels of purity.
BMT and GVHD Induction
Male CB6F1 mice aged 6-10 weeks received two 6.5 Gy doses of c-irradiation (.4 h apart) in a Gammacell 40 137 Cs irradiator (MDS Nordion, Ottawa ON) and were infused with 2610 6 TCD BM alone or with 10 6 CD4 + T cells, with/without 5610 6 purified DN T cells, as we previously reported [29] . Survival was monitored daily. Weights and clinical scores [50] were determined 2-3 times weekly. Moribund mice (score .6 or weight loss .25%) were sacrificed.
CFSE Suppression Assay
CD4
+ or CD8 + T cells (10 7 cells/mL) were incubated (10 minutes, 37uC) in PBS containing 1 mM CFSE (Invitrogen, Carlsbad CA), followed by quenching with FBS (Gibco, Carlsbad CA). Cells were washed in a-minimum essential medium with 10% FBS, 50 mM b-mercaptoethanol, 0.1 mg/mL penicillin and 0.1 mg/mL streptomycin (CM). 10 5 CFSE labelled cells were cultured for 5 days with 2610 5 irradiated (20 Gy) CB6F1 splenocytes and 50 U/mL recombinant human IL-2 (Proleukin, Chiron Corporation, Emeryville CA). Purified DN T cells (not CFSE labelled) were added in varying ratios. Cells were stained with 7-AAD (Sigma-Aldrich) prior to analysis to permit identification of dead cells. Percent suppression was calculated using the Proliferation of DN T cells in vitro was assessed by culturing in vivo-preactivated (by infusion of 4610 7 CB6F1 splenocytes 7 days prior) DN T cells for 3 days with irradiated CB6F1 splenocytes and 50 U/mL IL-2, followed by the addition of 1 mCi/well 3 H-thymidine. After 18 h, cultures were harvested and the cpm of retained DNA, determined on a TopCount NXT (Perkin-Elmer), was reported as an index of proliferation.
Adoptive Transfer Studies and in vivo Cell Tracking
LPR FcRc
+/+ and LPR FcRc 2/2 recipient mice for adoptive transfer studies were 4 weeks of age. CB6F1 recipients of BMT were 6-10 weeks of age. B6.GLD recipient mice were 6 weeks of age. Donor LPR FcRc 2/2 and LPR FcRc +/+ mice were generally 8-12 weeks of age to ensure the onset of DN T cell accumulation prior to use.
Proliferation of LPR FcRc +/+ CD8 + T cells in B6.SCID mice was assessed by labelling purified CD8 + T cells with CFSE at a concentration of 5 mM as described above. The cells were then injected (2.5610 6 /mouse) via the lateral tail vein alone or with 10 7 purified LPR FcRc 2/2 or LPR FcRc +/+ DN T cells. After 24 h, splenocytes were stained with anti-CD3 and anti-CD8 mAbs and examined for CFSE dilution in the CD3 + CD8 + gate by flow cytometry.
Measurement of Cell Cycling and Apoptosis with BrdU and Annexin V Labeling
LPR FcRc
+/+ and LPR FcRc 2/2 mice aged 8 weeks were fed BrdU in the drinking water at 0.8 mg/mL for 6 days. Their erythrocyte-free splenocytes were then stained for expression of TCRb, CD4, CD8, NK1.1. The cells were washed and then stained with PE-conjugated annexin V in annexin V binding buffer (BD Biosciences; 0.01M HEPES, 140 mM NaCl, 25 mM CaCl 2 ). After a further wash in annexin V binding buffer the cells were fixed using a BrdU staining kit (BD Biosciences). Nuclear DNA was digested with DNase I (Sigma) at 37uC for one hour prior to staining for BrdU epitopes. The stained cells were then analyzed by flow cytometry.
Supporting Information
Figure S1 Assessment of cell death and proliferation in CD16 hi , CD16 lo and LPR.FcRc 2/2 DN T cells. LPR.FcRc +/+ (n = 5) and LPR.FcRc 2/2 mice (n = 5) were fed BrdU in the drinking water for 6 days, and then their splenocytes were stained for expression of TCRb, CD16/32, CD4. CD8 and NK1.1 and with annexin V and analyzed by flow cytometry (same experiment as in Fig. 3B-C) . A. BrdU and Annexin V staining for the other 8 mice not shown in Fig. 3B (n = 4 LPR.FcRc +/+ , top 2 rows showing the CD16hi and CD16lo subsets gated as shown in Fig. 3B; and 
